GeneDx and Beren Therapeutics Partner to Accelerate Niemann-Pick…

Event summary

GeneDx and Beren Therapeutics launched the NPC GenomeComplete Sponsored Testing Program on September 9, 2026, offering no-cost comprehensive genome sequencing for eligible pediatric patients with suspected Niemann-Pick Disease Type C (NPC).
The program aims to address the diagnostic gap, with approximately two-thirds of NPC patients in the U.S. currently undiagnosed.
Rapid genome sequencing under the program can provide preliminary results in as soon as 48 hours for urgent medical decisions.
Beren Therapeutics fully sponsors the testing, eliminating financial and insurance-related barriers.

The big picture

This collaboration underscores the growing trend of biotech partnerships aimed at improving diagnostic capabilities for rare diseases. By combining GeneDx's genomic expertise with Beren Therapeutics' deep understanding of NPC, the program addresses a critical unmet need in pediatric neurology. The initiative also highlights the increasing importance of early diagnosis in progressive diseases where timely intervention can significantly impact patient outcomes.

What we're watching

Diagnostic Impact: How the NPC GenomeComplete program will affect the diagnosis rate of NPC, particularly for the infantile-onset form where only 37% of estimated cases are currently identified.
Strategic Alignment: Whether GeneDx can leverage this partnership to expand its rare disease diagnostic portfolio and strengthen its position in the genomic testing market.
Regulatory Dynamics: The pace at which regulatory approvals for NPC treatments may accelerate as more patients are diagnosed through this program.